Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL UTERINE FIBROIDS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL UTERINE FIBROIDS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL UTERINE FIBROIDS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 EPIDEMIOLOGY
6 PREMIUM INSIGHTS
6.1 PESTEL ANALYSIS
6.2 PORTER’S 5 FORCES
6.3 KEY STRATEGIC INITIATIVES
6.4 PATENT ANALYSIS
6.5 GLOBAL UTERINE FIBROIDS MARKET ANALYSIS (QUALITATIVE AND QUANTITATIVE ANALYSIS)
7 INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
7.2 KEY PRICING STRATEGIES
7.3 INTERVIEWS WITH DEVICE MANUFACTURERS
7.4 INTERVIEWS WITH DRUG MANUFACTURERS
7.5 OTHER KOL SNAPSHOTS
8 PIPELINE ANALYSIS
8.1 PHASE III CANDIDATES
8.2 PHASE II CANDIDATES
8.3 PHASE I CANDIDATES
8.4 OTHERS (PRE-CLINICAL AND RESEARCH)
9 REGULATORY FRAMWORK
10 GLOBAL UTERINE FIBROIDS MARKET, BY TYPE
10.1 OVERVIEW
10.2 SUBSEROSAL FIBROIDS
10.3 INTRAMURAL FIBROIDS
10.4 SUBMUCOSAL FIBROIDS
10.5 OTHERS
11 GLOBAL UTERINE FIBROIDS MARKET, BY DIAGNOSIS AND TREATMENT
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 ULTRASONOGRAPHY
11.2.2 MAGNETIC RESONANCE IMAGING (MRI)
11.2.3 COMPUTED TOMOGRAPHY
11.2.4 HYSTEROSCOPY
11.2.5 HYSTEROSALPINGOGRAPHY (HSG)
11.2.6 SONOHYSTEROGRAPHY
11.2.7 OTHERS
11.3 TREATMENT
11.3.1 MEDICATION
11.3.1.1. MEDICATION, BY TYPE
11.3.1.1.1. GNRH AGONISTS
11.3.1.1.1.1 BY TYPE
11.3.1.1.1.1.1. CETRORELIX
11.3.1.1.1.1.2. ELAGOLIX
11.3.1.1.1.1.3. LEUPRORELIN
11.3.1.1.1.1.4. OTHER
11.3.1.1.2. STEROIDS
11.3.1.1.3. CONTRACEPTIVES
11.3.1.1.3.1 BY TYPE
11.3.1.1.3.1.1. COMBINED ORAL CONTRACEPTIVES
11.3.1.1.3.1.2. PROGESTIN
I. MEDROXYPROGESTERONE ACETATE
II. NORETHINDRONE ACETATE
III. OTHERS
11.3.1.1.3.1.3. HORMONAL INTRAUTERINE DEVICES (IUDS)
11.3.1.1.4. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
11.3.1.1.4.1 BY TYPE
11.3.1.1.4.1.1. IBUPROFEN
11.3.1.1.4.1.2. NAPROXEN
11.3.1.1.4.1.3. MEFENAMIC ACID
11.3.1.1.4.1.4. OTHERS
11.3.1.1.5. VITAMINS
11.3.1.1.6. OTHERS
11.3.1.2. MEDICATION, BY PRESCRIPTION TYPE
11.3.1.2.1. PRESCRIPTION DRUGS
11.3.1.2.2. OTC DRUGS
11.3.1.3. MEDICATIONS, BY ROUTE OF ADMINISTRATION
11.3.1.3.1. ORAL MEDICATION
11.3.1.3.2. INEJCTABLE MEDICATIONS
11.3.1.3.3. TOPICAL MEDICATIONS
11.3.1.3.4. INTRAUTERINE DEVICES (IUDS)
11.3.2 SURGERY AND MEDICAL PROCEDURES
11.3.2.1. UTERINE FIBROID EMBOLIZATION
11.3.2.2. MAGNETIC RESONANCE GUIDED PROCEDURES
11.3.2.2.1. PERCUTANEOUS LASER ABLATION
11.3.2.2.2. TRANSCUTANEOUS FOCUSED ULTRASOUND
11.3.2.3. MYOLYSIS
11.3.2.4. ENDOMETRIAL ABLATION
11.3.2.5. HYSTERECTOMY
11.3.2.5.1. ABDOMINAL HYSTERECTOMY
11.3.2.5.2. VAGINAL HYSTERECTOMY
11.3.2.5.3. LAPAROSCOPIC HYSTERECTOMY
11.3.2.5.4. ROBOTIC-ASSISTED HYSTERECTOMY
11.3.2.5.5. OTHERS
11.3.2.6. MYOMECTOMY
11.3.2.6.1. MYOMECTOMY, BY TYPE
11.3.2.6.1.1 ABDOMINAL MYOMECTOMY
11.3.2.6.1.2 LAPAROSCOPIC MYOMECTOMY
11.3.2.6.1.3 HYSTEROSCOPIC MYOMECTOMY
11.3.2.6.1.4 OTHERS
12 GLOBAL UTERINE FIBROIDS MARKET, BY AGE GROUP
12.1 OVERVIEW
12.2 PREMENOPAUSAL WOMEN
12.3 POSTMENOPAUSAL WOMEN
13 GLOBAL UTERINE FIBROIDS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 AMBULATORY SURGICAL CENTERS
13.5 RESEARCH AND ACADEMIC INSTITUTES
13.6 HOMECARE SETTINGS
13.7 OTHERS
14 GLOBAL UTERINE FIBROIDS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDERS
14.3 RETAIL SALES
14.3.1 HOSPITAL PHARMACY
14.3.2 RETAIL PHARMACY
14.3.3 ONLINE PHARMACY
14.4 OTHERS
15 GLOBAL UTERINE FIBROIDS MARKET, BY COUNTRY
Global UTERINE FIBROIDS Market (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
15.2 EUROPE
15.2.1 GERMANY
15.2.2 U.K.
15.2.3 ITALY
15.2.4 FRANCE
15.2.5 SPAIN
15.2.6 RUSSIA
15.2.7 SWITZERLAND
15.2.8 TURKEY
15.2.9 BELGIUM
15.2.10 NETHERLANDS
15.2.11 DENMARK
15.2.12 SWEDEN
15.2.13 POLAND
15.2.14 NORWAY
15.2.15 FINLAND
15.2.16 REST OF EUROPE
15.3 ASIA-PACIFIC
15.3.1 JAPAN
15.3.2 CHINA
15.3.3 SOUTH KOREA
15.3.4 INDIA
15.3.5 AUSTRALIA
15.3.6 SINGAPORE
15.3.7 THAILAND
15.3.8 MALAYSIA
15.3.9 INDONESIA
15.3.10 NEW ZEALAND
15.3.11 VIETNAM
15.3.12 TAIWAN
15.3.13 PHILIPPINES
15.3.14 REST OF ASIA-PACIFIC
15.4 SOUTH AMERICA
15.4.1 BRAZIL
15.4.2 ARGENTINA
15.4.3 REST OF SOUTH AMERICA
15.5 MIDDLE EAST AND AFRICA
15.5.1 SOUTH AFRICA
15.5.2 SAUDI ARABIA
15.5.3 UAE
15.5.4 EGYPT
15.5.5 ISRAEL
15.5.6 OMAN
15.5.7 QATAR
15.5.8 BAHRAIN
15.5.9 REST OF MIDDLE EAST AND AFRICA
15.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
16 GLOBAL UTERINE FIBROIDS MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.3 COMPANY SHARE ANALYSIS: EUROPE
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16.5 MERGERS & ACQUISITIONS
16.6 NEW PRODUCT DEVELOPMENT & APPROVALS
16.7 EXPANSIONS
16.8 REGULATORY CHANGES
16.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
17 GLOBAL UTERINE FIBROIDS MARKET, SWOT AND DBMR ANALYSIS
18 GLOBAL UTERINE FIBROIDS MARKET, COMPANY PROFILE
18.1 PFIZER
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 ABBVIE
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 FERRING B.V
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 GLADFEM
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 DEBIOPHARM
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 BAYER AG
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 NOVARTIS
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 ASTRAZENECA
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 HOLOGIC INC.
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.1 A.R. LIFE SCIENCE
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 WEEFSEL PHARMA
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 DR. REDDY
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 WELLONA PHARMA
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 MERIL LIFE SCIENCES PVT LTD
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 MERCK
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 VERITY PHARMACEUTICALS, INC.
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 MYOVANT SCIENCES GMBH
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 ALLERGAN, INC.
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 MEDICINES360
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 GEDEON RICHTER PLC.
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 BOSTON SCIENTIFIC CORPORATION
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS
19 CONCLUSION
20 QUESTIONNAIRE
21 ABOUT DATA BRIDGE MARKET RESEARCH
